Questions about H1N1 Characteristics of the virus What are the symptoms? Same as general flu symptoms: sudden onset of fever, headache, cough, sore throat, aches; possibly vomiting and diarrhea What is the incubation period? 1 to 4 days What is the infectious period? 5+ days starting 1 day before symptoms (longer in children) What non-pharmaceutical interventions are recommended? Use good hand hygiene: wash hands with soap and water and use hand sanitizer Practice good cough etiquette: cough on shoulder away from people, not into hands Disinfect surfaces: especially tables and chairs, doorknobs, athletic equipment, toys, grocery carts Stay home when sick: stay home for at least 24 hours after fever is gone without the use of fever reducing medicine. Treat symptoms with rest, fluids and pain medication (NO ASPRIN for children). Vaccine implementation Who will receive the H1N1 vaccine? The target groups are:
• children and young people ages 6 months through 24 years
• household contacts of babies under 6 months of age
• health care and emergency medical services workers
• people between 25 and 64 years who have chronic medical conditions.
Once these groups have had the opportunity to receive vaccine, healthy individuals 25 years of age and older will be offered vaccine. How will it be distributed? The Department of State Health Services will coordinate the ordering and distribution of the novel H1N1 vaccine in Texas. Providers can register at ceive vaccines. How much will the vaccine cost? There is no cost for the vaccine; however, providers may charge an administration fee. The allowable amount has not been established. Will the regular influenza vaccine protect against H1N1? No, both seasonal and novel H1N1 vaccines are necessary to prevent illnesses from both viruses. The regular seasonal flu vaccine should be available in mid-September. How many doses will be needed? It is expected that 2 doses will be needed. When will the vaccine be available? The expected date is mid-October. Antiviral medication (Relenza and Tamiflu) What is it for? Antiviral medicine will be used to treat or help slow novel H1N1 influenza and allow the body’s normal immune system to respond Does it require a prescription? Yes, prescriptions are given based on healthcare provider decision and are targeted to high risk populations. Additional guidance is provided at When should it be given? Must be started within 48 hours of onset of symptoms (for maximum effectiveness) How will it be distributed? Through retail chain and independent pharmacies, community health centers, and local health departments How much will it cost? Individuals will pay the regular co-payment as required for all prescriptions. Anti-viral medication will be provided at no cost for patients who are uninsured or underinsured. Where can I get updated information? Sign up for email alerts Other contacts: Schools and health providers can call 1-866-623-6274 with questions. Helpful websites are:
Texas Department of State Health Services
Centers for Disease Control and Prevention
Texas Department of Agriculture
Texas Education Agency
School Closures: Based on the current severity of the disease, school closure is not recommended for disease control. School superintendents and county judges may initiate school closures. This decision will be based on the impact influenza has on the school (e.g. average daily attendance, staff absenteeism, and the school’s ability to function)
MATERIAL SAFETY DATA SHEET HARRY J. BOSWORTH COMPANY 7227 North Hamlin Avenue Skokie, Illinois 60076-3999 Information Phone: 847.679.3400 Emergency Phone: 800.535.5053 PRODUCT: Trim /Trim™ II/Trim™ Tints/Trim™ VW Powders Hazardous Components Physical/Chemical Characteristics 4. Cadmium pigments 6. Mineral pigment 4. N/A 4. Cadmium pigments 6.
Review and Perspective Infectious Diseases Biobanking as a catalyst towards personalized medicine: M. tuberculosis paradigm Fotini Betsou1* , Shreemanta K. Parida2, Martine Guillerm31Integrated Biobank of Luxembourg; 6 rue Ernest Barble, L-1210 Luxembourg2Vaccine Grand Challenges Program, Dept. of Biotechnology, Govt. of India, New Delhi,3The UNICEF/UNDP/World Bank/WHO Special P